The hidden threat: understanding anti-PF4 disorders without proximate heparin exposure.

Heparin-induced thrombocytopenia (HIT) is now recognized as one subset of a broader group of disorders: anti-platelet factor 4 (anti-PF4) disorders. This review provides an updated framework for anti-PF4 immunothrombosis without proximate heparin exposure-a clinical syndrome with phenotypic and laboratory features resembling classic HIT but with no recent heparin use (no heparin exposure within 14 days before onset). The core characteristics are a ≥50% platelet count decrease from baseline or an absolute platelet count <100×109/L, often associated with elevated arterial or venous thrombosis risk. Historically, these heparin-independent syndromes encompass spontaneous HIT-like syndrome, vaccine-induced immune thrombotic thrombocytopenia (VITT/TTS), and autoimmune HIT (aHIT)-notably, nearly all aHIT cases are initiated by prior heparin exposure before progressing to sustained heparin-independent platelet-activating antibodies. This review exclusively focuses on patients with no heparin exposure within 14 days of symptom onset, including: (1) patients with prior heparin exposure >14 days ago whose antibodies have evolved heparin-independent pathogenicity (aHIT), (2) patients with truly spontaneous HIT-like syndrome without any prior heparin, and (3) VITT. For aHIT specifically, prior heparin exposure is the initiating event in >95% of cases, but the antibodies become heparin-independent over time; thus these patients fall within our 14-day window of interest when presenting with delayed-onset thrombocytopenia beyond the acute heparin exposure phase. Pathogenesis centers on PF4-driven abnormal immune responses: PF4 forms complexes with polyanions (von Willebrand factor [VWF], pathogen surface molecules, etc.), inducing pathogenic antibodies that activate platelets via FcγRIIA, creating a self-amplifying "immune activation-thrombosis" cycle. Diagnosis requires combined clinical, laboratory, and imaging evaluation to distinguish from other thrombocytopenia-with-thrombosis disorders. Current treatment includes non-heparin anticoagulation plus high-dose IVIG for heparin-independent forms. Future research should validate diagnostic criteria, biomarkers, and targeted therapies.